142 related articles for article (PubMed ID: 7376686)
1. [Pharmacokinetics of trimethoprim and sulfametrol in patients with end stage renal failure and hemodialysis treatment (author's transl)].
Schmidt P; Korn A; Hitzenberger G; Zazgornik J; Kopsa H; Pils P
Wien Med Wochenschr; 1980 Feb; 130(4):171-3. PubMed ID: 7376686
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics, tolerance and therapeutic effect of trimethoprim-sulfametrol-infusions (author's transl)].
Breyer S; Graninger W; Hitzenberger G
Wien Med Wochenschr; 1980 Jun; 130(12):448-50. PubMed ID: 6999751
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of Lidaprim in cases of impaired renal function.
Hitzenberger G; Korn A; Pichler H; Bonelli J; Magometschnigg D
Int J Clin Pharmacol Biopharm; 1977 Jul; 15(7):310-4. PubMed ID: 892947
[TBL] [Abstract][Full Text] [Related]
4. [Sulfametrol-trimethoprim in the treatment of chronic urinary tract infections].
Pichler H; Kofler K; Ludvik W; Porpaczy P; Scherzer W
Acta Med Austriaca; 1975; 2(5):170-6. PubMed ID: 1220516
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.
Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S
Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of the bronchitic syndrome (author's transl)].
Danilewicz A; Kronberger O; Vogel D
Wien Klin Wochenschr; 1975 May; 87(9):313-5. PubMed ID: 1136518
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
8. [Tissue concentrations of sulfametrol-trimethoprim in the human prostate (author's transl)].
Bergmann M; Lederer B; Takacs F
Urologe A; 1979 Nov; 18(6):335-7. PubMed ID: 92090
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
[TBL] [Abstract][Full Text] [Related]
10. [Changes in trimethoprim levels and its pharmacokinetic parameters in children with chronic renal failure treated with biseptol. I].
Sieniawska M; Białasik D; Wróblewska-Kałuzewska M; Korniszewska J; Wierzbowska-Lange B; Karczeńska J; Wierzba K
Pediatr Pol; 1984 Mar; 59(3):177-87. PubMed ID: 6610853
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
[TBL] [Abstract][Full Text] [Related]
12. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of subacute pelvic inflammatory diseases with the antibiotic compound sulfametrol-trimethroprim (author's transl)].
Burmucic R; Zierler H; Steiner P
Wien Med Wochenschr; 1981 Sep; 131(17):431-4. PubMed ID: 7303713
[TBL] [Abstract][Full Text] [Related]
14. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
15. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
Balant L; Gorgia A; Marmy A; Tschopp JM
Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
[TBL] [Abstract][Full Text] [Related]
16. Accumulation of vitamin E metabolites in the blood of renal failure patients.
Galli F; Floridi AG; Floridi A; Buoncristiani U
Clin Nutr; 2004 Apr; 23(2):205-12. PubMed ID: 15030960
[TBL] [Abstract][Full Text] [Related]
17. [An absence of interaction of sulfametrol-trimethoprim with insulin or sulphonylurea derivatives in diabetics (author's transl)].
Kaspar L
Wien Klin Wochenschr; 1980 Apr; 92(8):276-9. PubMed ID: 6996341
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacokinetic and chemical investigations in children after oral administration of lidaprim (author's transl)].
Brandesky G; Takacs F
Wien Klin Wochenschr; 1975 Oct; 87(18):611-5. PubMed ID: 1220265
[TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
20. Isoniazid pharmacokinetics in patients in chronic renal failure.
Gold CH; Buchanan N; Tringham V; Viljoen M; Strickwold B; Moodley GP
Clin Nephrol; 1976 Aug; 6(2):365-9. PubMed ID: 954244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
